Halozyme Therapeutics, Inc. (HALO) Tops Q3 EPS by 9c, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $98.66 -2%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q3 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $22.9 million versus the consensus estimate of $19.25 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Reading (RDI) Tops Q2 EPS by 4c
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
